Corvus Pharmaceuticals Inc
CRVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$885.79M
Close$
$0.05
99.6% downside
Current Fair Value
99.6% downsideOvervalued by 99.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $885.79 Million |
|---|---|
| Enterprise Value | $867.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | 0.86 |
| Outstanding Shares | 92,368,013 |
Return
| Return on Equity | -24.02% |
|---|---|
| Return on Assets | -22.62% |
| Return on Invested Capital | -24.53% |
Valuation & Multiples
| P/E Ratio | -16.45 |
|---|---|
| PEG | -13.21 |
| Price to Sales | - |
| Price to Book Ratio | 5.27 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -15.68 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.25% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 76.54% |
|---|---|
| Total Invested | $2.72M▼ 99.74% |
| Investors Holding | 9▼ 179.00% |
ESG Score
No data
About Corvus Pharmaceuticals Inc
CEO: Richard Miller